Effects of Oral Iron Supplementation Before vs at Time of Vaccination on

Status Recruiting

Clinical Trial Summary

Iron deficiency (ID) anemia (IDA) is a global public health problem, with the highest prevalence in Africa. Vaccines often underperform in low- and middle-income countries (LMIC), and undernutrition, including ID, likely plays a role. Recent studies have shown the importance of iron status in vaccine response. Intravenous iron given at time of vaccination improved response to yellow fever and COVID-19 vaccines in IDA Kenyan women. Whether oral iron treatment would have a similar beneficial effect on vaccine response is uncertain. Also, timing of oral iron treatment needs further investigation. The co-primary objectives of this study are to assess 1) whether IDA in Kenyan women impairs vaccine response, and whether oral iron treatment improves their response; 2) the timing of oral iron treatment to improve vaccine response (prior to vaccination vs at time of vaccination). We will conduct a double-blind randomized controlled trial in southern Kenya to assess the effects of iron supplementation on response to three single-shot vaccines: Johnson & Johnson COVID- 19 (JJ COVID-19), the quadrivalent meningococcal vaccine (MenACWY) and the typhoid Vi polysaccharide vaccine (Typhim Vi). Women with IDA will be recruited and randomly assigned to three study groups: group 1 (pre- treatment) will receive 100 mg oral iron as ferrous sulfate (FeSO4) daily on days 1-56; group 2 (simultaneous treatment) will receive matching placebo daily on days 1-28, and 200 mg oral iron as FeSO4 daily on days 29-56; and group 3 (control) will receive matching placebo daily on days 1-56. Women in all groups will receive the JJ COVID-19 vaccine, the MenACWY and the Typhim Vi vaccine on day 28. Cellular immune response and serology will be measured at 28 days after vaccination in all groups.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06116669
Study type	Interventional
Source	Swiss Federal Institute of Technology
Contact	Giulia Pironaci, MSc
Phone	+41 44 632 93 29
Email	giulia.pironaci@hest.ethz.ch
Status	Recruiting
Phase	N/A
Start date	November 1, 2023
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06027801` - Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity	N/A
Completed	`NCT02282553` - Gastric Capsule Examination for Iron Deficiency Anaemia	N/A
Recruiting	`NCT05217836` - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting	`NCT04913649` - Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients	Phase 4
Completed	`NCT02176759` - Iron Absorption From Rice Fortified With Ferric Pyrophosphate	N/A
Completed	`NCT01438645` - ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy	N/A
Completed	`NCT01307007` - Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding	Phase 2
Completed	`NCT00982007` - Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)	Phase 3
Completed	`NCT00198848` - Iron Supplementation Among Adolescent Girls in India	N/A
Completed	`NCT01166451` - The Anemia Control Program: High or Low Iron Supplementation	N/A
Recruiting	`NCT03893045` - A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects	Phase 3
Recruiting	`NCT03817957` - Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency	Phase 3
Completed	`NCT03819530` - Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study	N/A
Completed	`NCT03618914` - Anemia and Inflammation
Completed	`NCT03940430` - Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students	Phase 2/Phase 3
Withdrawn	`NCT03873584` - Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
Enrolling by invitation	`NCT03897673` - Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas	N/A
Active, not recruiting	`NCT04778072` - A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects	N/A
Completed	`NCT03237065` - Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia	Phase 3
Completed	`NCT05153278` - IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women — DIVA_II

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms